Literature DB >> 6247989

Methyldopa. Mechanisms and treatment 25 years later.

E D Frohlich.   

Abstract

Methyldopa, an adrenergic-inhibiting compound, has been used for over 25 years as a safe and effective antihypertensive agent. The postulated mechanisms for the antihypertensive action of this compound have been varied and parallel our broadening knowledge of the role of the adrenergic nervous system in controlling arterial pressure. This review outlines the mechanisms of adrenergic control of the circulation and how the proposed mechanisms of action of methyldopa (ie, dopa decarboxylation, false neurotransmission, inhibition of renin release, and stimulation of alpha receptor sites in the brain) seem to account for the depressor action of the drug. Physiologic effects as well as immunologic and other clinical effects are also discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247989     DOI: 10.1001/archinte.140.7.954

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

Review 1.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

2.  Hypertension research program at ochsner: a program in translational research.

Authors:  Edward Frohlich
Journal:  Ochsner J       Date:  2002

Review 3.  Adverse effects of antihypertensive drugs.

Authors:  F E Husserl; F H Messerli
Journal:  Drugs       Date:  1981-09       Impact factor: 9.546

4.  Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy.

Authors:  Rebecca I Spain; Nicole K Andeen; Pamela C Gibson; Mary H Samuels; Cynthia D Morris; Andrew J Solomon; Richard Solomon; Carin Waslo; Rupali S Avasare
Journal:  Kidney Int       Date:  2021-10-16       Impact factor: 10.612

Review 5.  Should Renal Inflammation Be Targeted While Treating Hypertension?

Authors:  Sarika Chaudhari; Grace S Pham; Calvin D Brooks; Viet Q Dinh; Cassandra M Young-Stubbs; Caroline G Shimoura; Keisa W Mathis
Journal:  Front Physiol       Date:  2022-06-13       Impact factor: 4.755

Review 6.  Centrally acting antihypertensive agents: an update.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-05       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.